PL1919290T3 - Sposoby i produkty do leczenia chorób - Google Patents

Sposoby i produkty do leczenia chorób

Info

Publication number
PL1919290T3
PL1919290T3 PL06787393T PL06787393T PL1919290T3 PL 1919290 T3 PL1919290 T3 PL 1919290T3 PL 06787393 T PL06787393 T PL 06787393T PL 06787393 T PL06787393 T PL 06787393T PL 1919290 T3 PL1919290 T3 PL 1919290T3
Authority
PL
Poland
Prior art keywords
diseases
products
treatment
methods
Prior art date
Application number
PL06787393T
Other languages
English (en)
Inventor
David Bar-Or
Original Assignee
Ampio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ampio Pharmaceuticals Inc filed Critical Ampio Pharmaceuticals Inc
Publication of PL1919290T3 publication Critical patent/PL1919290T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation
PL06787393T 2005-07-12 2006-07-12 Sposoby i produkty do leczenia chorób PL1919290T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69872305P 2005-07-12 2005-07-12
US71115705P 2005-08-24 2005-08-24
US71115805P 2005-08-24 2005-08-24
PCT/US2006/027480 WO2007009087A2 (en) 2005-07-12 2006-07-12 Methods and products for treatment of diseases
EP06787393.5A EP1919290B1 (en) 2005-07-12 2006-07-12 Methods and products for treatment of diseases

Publications (1)

Publication Number Publication Date
PL1919290T3 true PL1919290T3 (pl) 2014-06-30

Family

ID=37637992

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06787393T PL1919290T3 (pl) 2005-07-12 2006-07-12 Sposoby i produkty do leczenia chorób

Country Status (12)

Country Link
US (3) US8722651B2 (pl)
EP (6) EP2446888A3 (pl)
JP (2) JP5544458B2 (pl)
CN (2) CN101282646B (pl)
DE (1) DE202006021081U1 (pl)
DK (1) DK1919290T3 (pl)
ES (1) ES2447025T3 (pl)
HK (2) HK1122470A1 (pl)
PL (1) PL1919290T3 (pl)
PT (1) PT1919290E (pl)
SI (1) SI1919290T1 (pl)
WO (1) WO2007009087A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765336A4 (en) 2004-06-25 2010-03-10 Univ Johns Hopkins ANGIOGENESIS INHIBITORS
ES2447025T3 (es) * 2005-07-12 2014-03-11 Ampio Pharmaceuticals, Inc. Métodos y productos para el tratamiento de enfermedades
FR2931678B1 (fr) * 2008-05-27 2010-10-01 Cll Pharma Utilisation du trilistane pour le traitement de la depression
EP2445350A4 (en) * 2009-06-22 2012-12-26 Dmi Acquisition Corp METHOD AND PRODUCTS FOR THE TREATMENT OF DISEASES
PL2554172T3 (pl) 2009-06-22 2015-03-31 Ampio Pharmaceuticals Inc Sposób leczenia chorób
EP2724721A1 (en) * 2012-10-26 2014-04-30 Matentzoglu, Konstantin Composition for use in the treatment of Angelman syndrome and/or autism spectrum disorder, the use of such composition and a method for manufacturing a medicament for the treatment of Angelman syndrome and/or autism spectrum disorder
AU2013361338A1 (en) * 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
CN107868117B (zh) * 2016-09-28 2021-04-23 中国科学院苏州纳米技术与纳米仿生研究所 司坦唑醇糖精盐及其制备方法和应用
EP3976019A4 (en) * 2019-06-03 2023-03-01 Aihol Corporation HYALURONAN CONJUGATES AND USES THEREOF
WO2021178448A1 (en) * 2020-03-02 2021-09-10 Motor Life Sciences, Llc Compositions and methods for diagnosing, preventing, and treating amyotrophic lateral sclerosis in patients with hypofunctional anti-trypsin activity

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
GB1123770A (en) 1966-11-15 1968-08-14 Sterling Drug Inc 2-cyano-3-oxo-steroids
US3296255A (en) 1963-11-29 1967-01-03 Sterling Drug Inc 2-cyano steroids
US3296295A (en) 1964-05-22 1967-01-03 Squibb & Sons Inc Norsteroids
US4160027A (en) * 1977-12-20 1979-07-03 Sterling Drug Inc. Steroid cyanoketones and intermediates
FR2502098A1 (fr) 1981-03-23 1982-09-24 Huret & Fils Dispositif perfectionne de fixation d'un derailleur sur une patte de cadre
ES526874A0 (es) 1982-11-02 1985-05-01 Sterwin Ag Procedimiento de trituracion de compuestos esteroides
US4994443A (en) * 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5714481A (en) * 1983-08-02 1998-02-03 Research Corporation Technologies, Inc. Derivatives of 5-androsten-17 ones and 5-androstan-17-ones
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4837212A (en) * 1984-11-15 1989-06-06 University Of Miami Treatment of hemolytic anemia with danazol
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
EP0244178A3 (en) * 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
DE3738620A1 (de) * 1987-11-13 1989-05-24 Luderschmidt Christoph Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
US5407926A (en) * 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
JP2680614B2 (ja) 1988-08-01 1997-11-19 日清製粉株式会社 ダナゾール組成物
US5990099A (en) * 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
ES2121570T3 (es) * 1989-07-07 1998-12-01 Endorecherche Inc Derivados de androgenos para uso en la inhibicion de la actividad de los esteroides sexuales.
US5972922A (en) * 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
AU657690B2 (en) 1990-06-11 1995-03-23 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
JPH04149132A (ja) 1990-10-13 1992-05-22 Bairon Boeki Kk ダナゾール水溶液
JPH0735335B2 (ja) 1991-02-28 1995-04-19 五十嵐 正雄 子宮内膜症の治療薬
US5506220A (en) * 1991-06-18 1996-04-09 Laboratoire Theramex Sa Anti-glaucomatous pharmaceutical composition and the process for obtaining them
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
DE69232925T2 (de) 1991-11-22 2003-06-18 Alcon Lab Inc Angiostatische steroide
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
GB9200210D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
AU674681B2 (en) * 1992-04-21 1997-01-09 Schepens Eye Research Institute, Inc., The Ocular androgen therapy in Sjogren's syndrome
US5240929A (en) * 1992-08-03 1993-08-31 Warner-Lambert Company 2-heterocyclic-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
WO1995003807A1 (en) * 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
EP0754046A1 (en) 1994-04-04 1997-01-22 FREEMAN, William R. Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
US5885591A (en) * 1996-07-02 1999-03-23 Johnson & Johnson Consumer Products, Inc. Personal lubricant compositions
US5929111A (en) * 1996-12-18 1999-07-27 Alcon Laboratories, Inc. A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
JP2004515446A (ja) * 1997-11-24 2004-05-27 ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド テストステロン阻害剤及びニューロンの保護のためのその用途
US6054446A (en) * 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
EP0939124A3 (en) 1998-02-24 2001-03-21 Smithkline Beecham Plc MGBP1 sequences
US6645954B2 (en) * 1998-04-09 2003-11-11 Multimed Limited Compositions comprising ethisterone or its derivatives
GB9807809D0 (en) 1998-04-09 1998-06-10 Multimed Ltd Compositions comprising ethisterone or its derivatives
EP1104302A4 (en) 1998-07-10 2006-08-09 Retmed Pty Ltd PROPHYLACTIC TREATMENTS OF BLOOD VESSEL NEOFORMATION IN MACULAR DEGENERATION
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
EP1074634B1 (en) 1999-07-09 2002-10-02 Institut Pasteur De Lille Method for the diagnosis or the prognosis of Alzheimer disease therapeutical composition for preventing or treating Alzheimer disease
US6610674B1 (en) * 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
PT1473003E (pt) * 1999-10-21 2008-12-26 Alcon Inc Dispositivo para administração de fármacos
WO2001030337A2 (en) 1999-10-22 2001-05-03 Orbon Corporation Ophthalmic formulation of dopamine antagonists
US6562369B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
GB2345851B (en) 2000-01-18 2004-05-26 Gavin Paul Vinson A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour
US20020055512A1 (en) * 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
DE60130872T2 (de) 2000-03-10 2008-07-17 Insite Vision, Inc., Alameda Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
US6555543B2 (en) 2000-08-04 2003-04-29 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US20040082557A1 (en) * 2001-01-26 2004-04-29 Wajszczuk Charles Paul Methods for treating estrogen-dependent disorders
CA2439687A1 (en) 2001-03-01 2002-09-12 Hollis-Eden Pharmaceuticals, Inc. Use of certain steroids for treatment of blood cell deficiencies
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
WO2002087543A1 (en) * 2001-05-01 2002-11-07 Biozone Laboratories, Inc. Sustained release formulations for nifedipine, dextromethorphan, and danazol
FR2825277B1 (fr) 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
US20030232798A1 (en) * 2001-06-12 2003-12-18 Yadon Arad Adrenal enzyme inhibitors
US20030050291A1 (en) * 2001-06-12 2003-03-13 Yadon Arad Adrenal enzyme inhibitors
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
EP1494699A4 (en) 2002-04-11 2009-07-22 Childrens Medical Center METHOD FOR INHIBITING VASCULAR HYPERPERMEABILITY
EP2298316A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
CA2509660C (en) * 2002-12-18 2011-08-30 Bruno De Lignieres (Deceased) Treatment of mastalgia with 4-hydroxy tamoxifen
JP5583310B2 (ja) 2002-12-20 2014-09-03 チャクシュ・リサーチ・インコーポレーテッド 眼球の症状の予防及び治療のための眼科用製剤
WO2004060322A2 (en) * 2003-01-02 2004-07-22 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
GB2400554B (en) 2003-04-16 2007-04-18 George Margetts Treatment of angiotensin II-induced cardiovascular disease
WO2004103406A1 (ja) 2003-05-26 2004-12-02 Japan Science And Technology Agency 血小板の減少または増加を伴う疾患の治療用組成物
GB0313612D0 (en) * 2003-06-12 2003-07-16 Novartis Ag Organic compounds
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
EP1691795A2 (en) * 2003-12-03 2006-08-23 LifeCycle Pharma A/S Pharmaceutical compositions comprising danazol
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20050143362A1 (en) * 2003-12-31 2005-06-30 Mclane Michael W. Danazol for treatment of hypogonadism in the adult male
US7442681B2 (en) * 2004-02-10 2008-10-28 University Of Virginia Patent Foundation Method of inhibiting vascular permeability
CA2557724A1 (en) 2004-02-27 2005-10-06 Centocor, Inc. Methods and compositions for treating il-13 related pathologies
WO2005097121A1 (en) 2004-04-06 2005-10-20 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
EP1765336A4 (en) * 2004-06-25 2010-03-10 Univ Johns Hopkins ANGIOGENESIS INHIBITORS
GB2420281A (en) 2004-11-22 2006-05-24 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of dermatological conditions
GB2421183A (en) 2004-12-17 2006-06-21 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of skin cancers
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
EP1861106A2 (en) 2005-03-02 2007-12-05 Inc. Nascent Pharmaceutical Combination therapy for topical application in the treatment of age-related macular degeneration and ocular hypertension
ES2447025T3 (es) * 2005-07-12 2014-03-11 Ampio Pharmaceuticals, Inc. Métodos y productos para el tratamiento de enfermedades
US7598181B2 (en) * 2005-07-19 2009-10-06 Micron Technology, Inc. Process for enhancing solubility and reaction rates in supercritical fluids
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
WO2009146320A1 (en) * 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
PL2554172T3 (pl) * 2009-06-22 2015-03-31 Ampio Pharmaceuticals Inc Sposób leczenia chorób
EP2445350A4 (en) * 2009-06-22 2012-12-26 Dmi Acquisition Corp METHOD AND PRODUCTS FOR THE TREATMENT OF DISEASES

Also Published As

Publication number Publication date
EP1919290A2 (en) 2008-05-14
PT1919290E (pt) 2014-03-20
HK1171972A1 (zh) 2013-04-12
SI1919290T1 (sl) 2014-05-30
EP2446888A3 (en) 2012-08-15
EP2446887A3 (en) 2012-08-15
EP2446887A2 (en) 2012-05-02
EP1919290B1 (en) 2014-01-22
EP2468282A3 (en) 2012-09-12
CN101282646B (zh) 2013-03-27
CN101282646A (zh) 2008-10-08
US20070111972A1 (en) 2007-05-17
DE202006021081U1 (de) 2012-05-08
US8722651B2 (en) 2014-05-13
EP2468282A2 (en) 2012-06-27
HK1122470A1 (en) 2009-05-22
EP2468318A1 (en) 2012-06-27
EP1919290A4 (en) 2009-10-28
ES2447025T3 (es) 2014-03-11
DK1919290T3 (da) 2014-04-22
EP2462959B1 (en) 2016-06-22
EP2446888A2 (en) 2012-05-02
EP2462959A1 (en) 2012-06-13
WO2007009087A2 (en) 2007-01-18
JP5544458B2 (ja) 2014-07-09
JP5779618B2 (ja) 2015-09-16
CN103169714A (zh) 2013-06-26
JP2009505950A (ja) 2009-02-12
WO2007009087A3 (en) 2007-07-12
US20110171307A1 (en) 2011-07-14
US8586568B2 (en) 2013-11-19
US20110171306A1 (en) 2011-07-14
JP2013213059A (ja) 2013-10-17

Similar Documents

Publication Publication Date Title
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
HK1171972A1 (zh) 治療疾病的方法和產品
EP1968607A4 (en) TREATMENT OF CANCER AND OTHER DISEASES
IL193473A0 (en) Amide derivatives and their application for the treatment of g protein related diseases
EP1933880A4 (en) OLIGORIBONUCLEOTIDES AND METHODS OF USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES
IL189528A0 (en) Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
EP1737482A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
IL185256A0 (en) Method and composition for treating peripheral vascular diseases
EP1893043A4 (en) TOBACCO PRODUCTS WITH REDUCED RISKS AND PROCESS FOR PRODUCING THE SAME
IL182643A0 (en) Novel composition and methods for the treatment of immune related diseases
EP1962869A4 (en) TREATMENT OF RESPIRATORY DISEASES
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
EP1858524A4 (en) COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND RELATED DISEASES
GB2445651B (en) Well treatment products and methods of using them
EP1812797A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HYPERPROLIFERATIVE DISEASES
ZA200806095B (en) Means and methods for the treatment of tumorous diseases
EP2007790A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN
IL201376A0 (en) Products for prophylaxis and /or treatment of viral diseases and method of making and using same
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
EP1924286A4 (en) PROPHYLACTIC AND / OR THERAPEUTIC METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES
IL188010A0 (en) Procedure for the treatment of purines and products thereof
GB0422634D0 (en) Method of treating skin diseases
GB2442881B (en) Methods for altering gene expression and methods of treatment utilizing same
EP1846013A4 (en) TREATMENT OF SKIN DISEASES
IL191887A0 (en) Method for the diagnosis and treatment of cardiovascular diseases